Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

X
Trial Profile

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TAS-CC3
  • Most Recent Events

    • 01 Jun 2021 Results of post-hoc analysis assessing predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS, published in the Anticancer Research.
    • 25 Jan 2020 Results of post hoc analysis assessing pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy presented at the 2020 Gastrointestinal Cancers Symposium
    • 19 Jan 2019 Primary endpoint (Progression free survival) has been met as per the results presented at the 2019 Gastrointestinal Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top